23andMe Holding Co. (NASDAQ:ME) Q4 2023 Results Conference Call May 25, 2023 4:30 PM ET

Company Participants

Maeve Conneighton - Investor Relations at Argo Partners

Anne Wojcicki - Chief Executive Officer & Co-Founder

Joe Selsavage - Interim Chief Financial Officer & Accounting Officer

Kenneth Hillan - Chief Therapeutics Officer

Conference Call Participants

Daniel Grosslight - Citi

Steven Mah - Cowen

Operator

Hello, and welcome to 23andMe's Fiscal Year 2023 Fourth Quarter and Full Year Financial Results Conference Call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prepared remarks, there will a question-and-answer session.

I would now like to turn the call over to Maeve Conneighton, Investor Relations at Argo Partners to lead off the call. Thank you. Please go ahead.

Maeve Conneighton

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the quarter and full year. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event.

Please note that certain statements made during this call regarding matters that are not historical facts including, but not limited to, management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call.

Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release.

Joining us on today's call are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Joe Selsavage, our Interim Chief Financial and Accounting Officer; Kenneth Hillan, our Chief Therapeutics Officer, will join us for Q&A.

I'd now like to turn the call over to Anne.

Anne Wojcicki

Thank you, Maeve. 23andMe had a productive year with numerous accomplishments for both our consumer and therapeutics businesses. Since starting the Company, 23andMe has been focused on helping our customers' access, understand and benefit from the human genome. Today, I'm excited to review the progress we made in those areas this past quarter and fiscal year 2023.